[go: up one dir, main page]

MA40801A1 - Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 - Google Patents

Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Info

Publication number
MA40801A1
MA40801A1 MA40801A MA40801A MA40801A1 MA 40801 A1 MA40801 A1 MA 40801A1 MA 40801 A MA40801 A MA 40801A MA 40801 A MA40801 A MA 40801A MA 40801 A1 MA40801 A1 MA 40801A1
Authority
MA
Morocco
Prior art keywords
antibody
bispecific antibodies
binding specifically
antibodies binding
relates
Prior art date
Application number
MA40801A
Other languages
English (en)
Other versions
MA40801B2 (fr
Inventor
Jana Albrecht
Cédric Barriere
Christian Beil
Jochen Beninga
Chantal Carrez
Stéphane Guerif
Katja Kroll
Christian Lange
Cendrine Lemoine
Wulf-Dirk Leuschner
Ercole Rao
Marion Schneider
Marie-Cécile Wetzel
Peter Wonerow
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA40801A1 publication Critical patent/MA40801A1/fr
Publication of MA40801B2 publication Critical patent/MA40801B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/575—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une protéine de liaison de type anticorps se liant spécifiquement à cd3 et se liant de façon spécifique à au moins un autre antigène, par exemple cd123. La présente invention concerne également une protéine de liaison de type anticorps se liant spécifiquement à cd123 et se liant de façon spécifique à au moins un autre antigène. L'invention concerne en outre des anticorps anti-cd3 et des anticorps anti-cd123. L'invention concerne également des compositions pharmaceutiques com
MA40801A 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 MA40801B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305077 2015-01-23
PCT/EP2016/051386 WO2016116626A1 (fr) 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Publications (2)

Publication Number Publication Date
MA40801A1 true MA40801A1 (fr) 2018-07-31
MA40801B2 MA40801B2 (fr) 2024-09-30

Family

ID=52434717

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40801A MA40801B2 (fr) 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Country Status (37)

Country Link
US (3) US20180057597A1 (fr)
EP (3) EP4039710A3 (fr)
JP (3) JP6817211B2 (fr)
KR (2) KR102680151B1 (fr)
CN (4) CN107428835B (fr)
AR (1) AR103488A1 (fr)
AU (2) AU2016210068B2 (fr)
BR (1) BR112017014805A2 (fr)
CA (2) CA2974453A1 (fr)
CL (2) CL2017001866A1 (fr)
CO (1) CO2017008462A2 (fr)
CR (1) CR20170383A (fr)
DO (1) DOP2017000160A (fr)
EA (1) EA201791666A1 (fr)
EC (1) ECSP17054182A (fr)
ES (1) ES2824167T3 (fr)
GT (1) GT201700162A (fr)
HR (1) HRP20201517T1 (fr)
HU (1) HUE052011T2 (fr)
IL (2) IL299975A (fr)
LT (1) LT3247725T (fr)
MA (1) MA40801B2 (fr)
MX (3) MX386535B (fr)
MY (2) MY191964A (fr)
NZ (1) NZ734803A (fr)
PE (1) PE20171764A1 (fr)
PH (1) PH12017501190B1 (fr)
PL (1) PL3247725T3 (fr)
PT (1) PT3247725T (fr)
RS (1) RS60916B1 (fr)
SG (2) SG10201906762YA (fr)
SI (1) SI3247725T1 (fr)
TN (3) TN2018000324A1 (fr)
TW (3) TW202130662A (fr)
UA (1) UA126269C2 (fr)
UY (1) UY36536A (fr)
WO (1) WO2016116626A1 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR102680151B1 (ko) * 2015-01-23 2024-07-03 사노피 항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
PE20181167A1 (es) 2015-10-25 2018-07-19 Sanofi Sa Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
MX2018012566A (es) 2016-04-13 2019-08-05 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes.
FI3443006T3 (fi) 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
EP3471754A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anticorps anti-pd-l1
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
MX2019003225A (es) 2016-09-21 2019-06-10 Aptevo Res & Development Llc Proteínas de unión a cd123 y composiciones y métodos relacionados.
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CA3048174A1 (fr) * 2016-12-22 2018-06-28 Daiichi Sankyo Company, Limited Anticorps anti-cd3 et molecule contenant ledit anticorps
TW201837174A (zh) * 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
KR20250121461A (ko) * 2017-05-08 2025-08-12 아디맵 엘엘씨 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법
WO2018218207A1 (fr) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anticorps anti-cd33 et leurs utilisations
EP3409322A1 (fr) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Procédés de traitement
AU2018290228B2 (en) 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
US11525004B2 (en) 2017-07-20 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Recombinant CD123-binding antibodies
MX2020003087A (es) * 2017-09-21 2020-08-17 Wuxi Biologics Ireland Ltd Anticuerpos anti-cd3epsilon novedosos.
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
WO2019070013A1 (fr) 2017-10-05 2019-04-11 第一三共株式会社 Composition pour déplétion de lymphocytes t cytotoxiques
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
AU2018357221B2 (en) * 2017-10-27 2025-08-28 Pfizer Inc. Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
KR102737364B1 (ko) 2018-01-12 2024-12-05 젠자임 코포레이션 폴리펩티드의 정량화를 위한 방법
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
DK3802608T3 (da) * 2018-05-24 2025-06-10 Janssen Biotech Inc Anti-cd3-antistoffer og anvendelser deraf
US12404328B2 (en) * 2018-06-07 2025-09-02 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
WO2019237350A1 (fr) * 2018-06-15 2019-12-19 康源博创生物科技(北京)有限公司 Anticorps anti-cd123, son procédé de préparation et son utilisation
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
US20210269525A1 (en) * 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
EP3849565A4 (fr) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
MY209796A (en) * 2018-12-11 2025-08-05 Q32 Bio Inc Fusion protein constructs for complement associated disease
US11965030B2 (en) 2018-12-24 2024-04-23 Sanofi Multispecific binding proteins with mutant fab domains
MY208876A (en) * 2019-04-09 2025-06-05 Sanofi Sa Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20220289856A1 (en) * 2019-08-17 2022-09-15 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
JP7227895B2 (ja) * 2019-12-23 2023-02-22 株式会社堀場製作所 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット
JP2023525423A (ja) 2020-01-15 2023-06-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
CN111171155B (zh) * 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 抗cd3和cd123双特异性抗体及其用途
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
BR112022023978A2 (pt) * 2020-05-27 2023-02-07 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno cd3 e usos dos mesmos
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
MX2023007901A (es) * 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
WO2022150792A1 (fr) * 2021-01-11 2022-07-14 Soteria Biotherapeutics, Inc. Compositions d'engagement de lymphocytes t de dimérisation chimique à base d'indinavir
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
WO2022184805A1 (fr) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité
WO2022199555A1 (fr) * 2021-03-23 2022-09-29 Guangzhou Lintonpharm Co., Ltd. Protéine de liaison à un antigène multispécifique se liant à cd3 et son utilisation
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
US20240376208A1 (en) 2021-07-30 2024-11-14 Affimed Gmbh Duplexbodies
WO2023036326A1 (fr) * 2021-09-13 2023-03-16 江苏先声药业有限公司 Anticorps anti-cd3 humain et son utilisation
CN118510803A (zh) * 2021-10-12 2024-08-16 乐普创一生物科技（上海）有限公司 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
WO2023072217A1 (fr) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Protéines de fusion ciblant cd3 et cd47
IL312060A (en) 2021-11-03 2024-06-01 Affimed Gmbh Bispecific CD16A binders
EP4198052A1 (fr) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides et protéines de liaison d'antigène pour utilisation dans l'immunothérapie contre le carcinome hépatocellulaire fibrolamellaire (fl-hcc) et autres cancers
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023150518A1 (fr) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
WO2023179716A1 (fr) * 2022-03-23 2023-09-28 上海济煜医药科技有限公司 Anticorps anti-cd3, son procédé de préparation et son utilisation
WO2023183600A1 (fr) * 2022-03-25 2023-09-28 Washington University Systèmes et procédés de surveillance de l'efficacité d'un traitement cytotoxique
JP2025510232A (ja) 2022-03-29 2025-04-14 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｉｌｔ３及びｃｄ３結合剤及びその使用方法
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
WO2023227790A1 (fr) 2022-05-27 2023-11-30 Sanofi Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc
EP4543930A2 (fr) * 2022-06-22 2025-04-30 The Regents of The University of Michigan Compositions et méthodes de traitement d'ides ciblés de troubles liés à l'igg
WO2024044655A1 (fr) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Administration de protéines hétérologues
EP4592316A1 (fr) * 2022-09-23 2025-07-30 Lindis Biotech GmbH Protéine de liaison à l'antigène isolée et son utilisation
WO2024088987A1 (fr) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202506727A (zh) * 2023-04-10 2025-02-16 美商麥迪紐有限責任公司 優化的ｃｄ３抗原結合結構域
WO2024220597A2 (fr) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Dosage numérique utilisant des gouttelettes pour détecter un vecteur lentiviral compétent pour la réplication
WO2024243340A1 (fr) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Fusogènes en tandem et particules lipidiques associées
WO2025109119A1 (fr) 2023-11-22 2025-05-30 Priothera Sas Procédés de traitement avec des protéines multispécifiques de liaison à l'antigène en combinaison avec des modulateurs du récepteur s1p
WO2025131075A1 (fr) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 Anticorps multispécifiques anti-cd3 et anti-cd3, et utilisation
WO2025184529A1 (fr) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Particules virales à présentation fusogène et compositions et procédés associés
WO2025233432A1 (fr) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Utilisation et dosage d'une protéine de liaison à l'antigène comprenant un tcr spécifique d'un peptide restreint par hla-a*02
WO2026006495A1 (fr) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anticorps anti-wt1/hla-a2 et ses utilisations
WO2026006492A2 (fr) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anticorps anti-prame/hla-a2 et leurs utilisations

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204A (en) 1847-07-24 james cantelo
US244A (en) 1837-06-30 Edward flint
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2071478A1 (fr) 1989-10-27 1991-04-28 Jeffery A. Bluestone Methodes et compositions favorisant l'immunopotentialisation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL100460A (en) 1990-12-20 1997-06-10 Ixsys Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994019478A1 (fr) 1993-02-22 1994-09-01 The Rockefeller University Production de retrovirus exempts d'auxiliaires, a titre eleve par transfection transitoire
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
HU221385B1 (en) 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2205007C (fr) 1995-09-11 2010-12-14 Masamichi Koike Anticorpos de la chaine alpha du recepteur de l'interleukine 5 humaine
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
EP0971952A2 (fr) 1997-04-10 2000-01-19 Royal Netherlands Academy of Arts and Sciences Reactifs pour diagnostics et procede correspondant
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
JP2004509835A (ja) 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
RS58217B1 (sr) * 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
TR201807983T4 (tr) 2007-08-29 2018-06-21 Sanofi Sa İnsanlaştırılmış anti-CXCR5 antikorları, deriveleri ve kullanımları.
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
EP2949673A1 (fr) 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-il-3ra destiné à être utilisé dans le traitement d'une tumeur sanguine
CN103002913B (zh) 2010-02-17 2015-12-16 Csl有限公司 靶向产生i型干扰素的细胞的组合物和方法
WO2011109588A1 (fr) * 2010-03-03 2011-09-09 Health Research Inc. Nouveaux immunogènes et anticorps cd3 epsilon
PL2582390T3 (pl) * 2010-06-15 2015-05-29 Csl Ltd Sposób immunoterapeutyczny obejmujący przeciwciała przeciwko CD123 (IL-3R) oraz kompleks immunostymulacyjny
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
HRP20190756T1 (hr) 2011-05-21 2019-06-14 Macrogenics, Inc. Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3
CN102796198A (zh) 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3的融合蛋白、制备方法及其用途
CN102796199A (zh) * 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
BR112014019116B1 (pt) 2012-02-03 2024-01-23 F.Hoffmann-La Roche Ag Kit, moléculas de anticorpo e uso de uma molécula de anticorpo
EP2839019A4 (fr) 2012-04-20 2016-03-30 Emergent Product Dev Seattle Polypeptides se liant à cd3
EP4053162A1 (fr) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3
WO2014106004A2 (fr) 2012-12-28 2014-07-03 Abbvie, Inc. Système et procédé à haut débit d'identification d'anticorps ayant des activités de liaison à un antigène spécifique
JP2016093104A (ja) * 2013-02-19 2016-05-26 国立大学法人京都大学 抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
IL289918B2 (en) * 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
WO2014138819A1 (fr) 2013-03-14 2014-09-18 Csl Limited Agents qui neutralisent la signalisation par il-3 et leurs utilisations
WO2014138805A1 (fr) * 2013-03-14 2014-09-18 Csl Limited Agents anti-il-3r alpha et leurs utilisations
US9683039B2 (en) * 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP2970484B2 (fr) 2013-03-15 2022-09-21 Amgen Inc. Anticorps hétérodimères bispécifiques
EP2789630A1 (fr) * 2013-04-09 2014-10-15 EngMab AG Anticorps bispécifiques contre le CD3e et ROR1
HK1217023A1 (zh) * 2013-05-28 2016-12-16 Numab Innovation Ag 新型抗体
EP2839842A1 (fr) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
CA2959171C (fr) 2014-09-05 2023-11-14 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
KR102680151B1 (ko) * 2015-01-23 2024-07-03 사노피 항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
EP3236996B1 (fr) 2015-05-08 2022-03-16 Xencor, Inc. Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
MX2018012566A (es) * 2016-04-13 2019-08-05 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes.
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
JP7036909B2 (ja) * 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
MX2021004147A (es) * 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.

Also Published As

Publication number Publication date
NZ772084A (en) 2024-10-25
CN107428835A (zh) 2017-12-01
ECSP17054182A (es) 2017-11-30
TN2017000275A1 (en) 2018-10-19
US20210292423A1 (en) 2021-09-23
US20180222987A1 (en) 2018-08-09
EA201791666A1 (ru) 2017-11-30
MX2021011697A (es) 2021-10-22
AR103488A1 (es) 2017-05-10
TW202402802A (zh) 2024-01-16
CR20170383A (es) 2017-11-22
TW202130662A (zh) 2021-08-16
KR20170101311A (ko) 2017-09-05
AU2022200467B2 (en) 2025-08-14
EP4039710A3 (fr) 2022-10-19
EP3812398A3 (fr) 2021-07-21
TN2018000325A1 (en) 2020-01-16
AU2022200467A1 (en) 2022-02-17
IL299975A (en) 2023-03-01
EP3247725B1 (fr) 2020-07-01
IL253569A0 (en) 2017-09-28
CN114230668B (zh) 2025-07-11
NZ772085A (en) 2024-07-05
MX2021011696A (es) 2021-10-22
SG10201906762YA (en) 2019-09-27
LT3247725T (lt) 2020-10-12
MA40801B2 (fr) 2024-09-30
BR112017014805A2 (pt) 2018-01-09
CL2017001866A1 (es) 2018-04-27
SI3247725T1 (sl) 2020-11-30
MX386535B (es) 2025-03-19
NZ734803A (en) 2023-03-31
TN2018000324A1 (en) 2020-01-16
CA3251582A1 (en) 2025-11-29
MX2017009535A (es) 2017-11-02
JP2023093625A (ja) 2023-07-04
KR102680151B1 (ko) 2024-07-03
KR20240104220A (ko) 2024-07-04
US10906978B2 (en) 2021-02-02
PH12017501190A1 (en) 2017-12-18
HRP20201517T1 (hr) 2020-12-11
CA2974453A1 (fr) 2016-07-28
WO2016116626A1 (fr) 2016-07-28
JP2021072784A (ja) 2021-05-13
TW201639885A (zh) 2016-11-16
GT201700162A (es) 2018-10-24
PT3247725T (pt) 2020-10-07
CL2018002490A1 (es) 2019-07-26
CN114230668A (zh) 2022-03-25
UA126269C2 (uk) 2022-09-14
CO2017008462A2 (es) 2018-01-16
EP3247725A1 (fr) 2017-11-29
CN107428835B (zh) 2021-11-26
CN120988137A (zh) 2025-11-21
JP2018513831A (ja) 2018-05-31
EP3812398A2 (fr) 2021-04-28
HUE052011T2 (hu) 2021-04-28
EP4039710A2 (fr) 2022-08-10
IL253569B2 (en) 2023-06-01
DOP2017000160A (es) 2017-08-15
ES2824167T3 (es) 2021-05-11
MY202412A (en) 2024-04-27
PE20171764A1 (es) 2017-12-21
JP7269215B2 (ja) 2023-05-08
AU2016210068B2 (en) 2021-10-28
MY191964A (en) 2022-07-21
PH12017501190B1 (en) 2024-01-17
TWI726862B (zh) 2021-05-11
US20180057597A1 (en) 2018-03-01
JP6817211B2 (ja) 2021-01-20
PL3247725T3 (pl) 2021-01-11
UY36536A (es) 2016-08-31
CN114230667A (zh) 2022-03-25
SG11201705925PA (en) 2017-08-30
RS60916B1 (sr) 2020-11-30
JP7692448B2 (ja) 2025-06-13

Similar Documents

Publication Publication Date Title
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA38498A1 (fr) Protéines de liaison anti-lag-3
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA49038B1 (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2020000435A (es) Anticuerpos anti-cd166 y usos de estos.
MA41867B1 (fr) Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA38161A1 (fr) Anticorps anti-bmp-6
MA39090A1 (fr) Anticorps anti-ccl17
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
WO2018094300A8 (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
CL2020002459A1 (es) Variantes de anticuerpo c-terminales